Rivastigmine 0.192 mg/HR [Exelon]
RxNorm 751301

Concept Hierarchy & Relationship Mapping

RxNorm Concept Unique Identifier (RxCUI) 751301 represents a standardized clinical drug concept used for cross-system interoperability. This concept aggregates multiple Atom IDs (AUIs), which are specific naming variations and synonyms used across pharmaceutical databases to ensure accurate medication mapping for: rivastigmine 0.192 mg/HR [Exelon].

The following semantic concepts and normalized strings are associated with this clinical entity:

SBDC
Rivastigmine 0.192 mg/HR [Exelon]
AUI:2762506
View

This clinical crossover tool is designed for healthcare professionals, pharmacists, and data analysts to safely compare substitute products and manage medication interoperability.

SBDCPrescribable

Semantic Branded Drug Component (SBDC):
Rivastigmine 0.192 mg/HR [Exelon]
(Atom ID: 2762506)

Clinical Status & Identity

Prescribable Status
YES (Active)
Part of the RxNorm Current Prescribable Content subset including all drugs available for prescription in the USA.
Concept Description
rivastigmine 0.192 MG/HR [Exelon]
Official description of the drug concept as defined in the source vocabulary.
Suppress Flag
N
N: Not suppressible | O: Obsolete | Y: Suppressed by editor | E: Unquantified non-prescribable drug.

Interoperability & Coding

Concept ID (RxCUI)
751301
RxNorm Unique Identifier for the standardized concept.
Atom ID (RXAUI)
2762506
Unique identifier for this specific name variation (Atom).
Term Type (TTY)
SBDC
Semantic Branded Drug Component (Ingredient + Strength + Brand Name)
Source Code
751301
The "Most useful" identifier asserted by the original source vocabulary.

Source & Registry Data

Source Name
RxNorm Vocabulary (RXNORM)
The official name and abbreviation for the vocabulary source.
Source Version
20AA_260601F
The specific version of the vocabulary provided by the source.
Update Date
June 01, 2026
The date when this RxNorm data was last updated by the NLM.
License Contact
RxNorm Customer Service, , U.S. National Library of Medicine, 8600 Rockville Pike, , Bethesda, MD, United States, 20894, (888) FIND-NLM, , https://support.nlm.nih.gov/support/create-case/, https://www.nlm.nih.gov/research/umls/rxnorm/
Source licensing contact information.

Patient Education

Rivastigmine


Rivastigmine is used to treat dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) in people with Alzheimer's disease (a brain disease that slowly destroys the memory and ability to think, learn, communicate and handle daily activities). Rivastigmine is also used to treat dementia in people with Parkinson's disease (a brain and nervous system disease with symptoms of slowing of movement, muscle weakness, shuffling walk, and loss of memory). Rivastigmine is in a class of medications called cholinesterase inhibitors. It improves mental function (such as memory and thinking) by increasing the amount of a certain natural substance in the brain.
[Learn More]


Rivastigmine Transdermal Patch


Rivastigmine transdermal patches are used to treat dementia (a brain disorder that affects the ability to remember, think clearly, communicate, and perform daily activities and may cause changes in mood and personality) in people with Alzheimer's disease (a brain disease that slowly destroys the memory and the ability to think, learn, communicate and handle daily activities). Transdermal rivastigmine is also used to treat dementia in people with Parkinson's disease (a brain system disease with symptoms of slowing of movement, muscle weakness, shuffling walk, and loss of memory). Rivastigmine is in a class of medications called cholinesterase inhibitors. It improves mental function (such as memory and thinking) by increasing the amount of a certain natural substance in the brain.
[Learn More]


* Please review the disclaimer below.